Physician profile
Robert J Audet
NPI 1659360311
$4,360.12
in general payments reported to CMS, 2019-2025
29 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $429 · 2021: $479 · 2022: $559 · 2023: $507 · 2024: $553 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,153.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $688.36 | 2019-2025 | Proclaim, Eterna |
| Abbvie INC. | $584.44 | 2021-2025 | Qulipta |
| Boston Scientific Corporation | $380.77 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Lundbeck LLC | $307.09 | 2022-2025 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $289.87 | 2021-2025 | Relistor |
| Pfizer INC. | $286.33 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $272.51 | 2019-2025 | Xtampza, Belbuca |
| Daiichi Sankyo INC. | $181.38 | 2019 | |
| Bioventus LLC | $168.63 | 2022-2025 | Supartz Fx Sodium Hyaluronate, Gelsyn-3 |
| Biohaven Pharmaceuticals, INC. | $146.18 | 2021 | |
| Lilly USA, LLC | $131.89 | 2019-2022 | |
| Amgen INC. | $109.00 | 2019-2022 | |
| Eisai INC. | $93.58 | 2020-2022 | |
| Biodelivery Sciences International, INC. | $92.44 | 2019-2021 | |
| Medtronic USA, INC. | $89.28 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $79.04 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $77.41 | 2019-2022 | |
| Allergan, INC. | $45.67 | 2020 | |
| Tersera Therapeutics LLC | $41.04 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $38.00 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.55 | 2022 | |
| Kaleo, INC. | $34.44 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.74 | 2019 | |
| Idorsia Pharmaceuticals US INC | $30.64 | 2023 | Quviviq |
| Tonix Medicines, INC. | $29.69 | 2025 | Tonmya |
| Takeda Pharmaceuticals U.S.A., INC. | $28.31 | 2019 | |
| Shionogi INC | $27.60 | 2019 | |
| Novo Nordisk INC | $26.68 | 2025 | Wegovy |
| Avanos Medical | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Audet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.